Skip to main content
SpringerLink
Log in

The Danish Health and Medicines Authority has issued guidance regarding the risk of renal impairment with mesalazine [Asacol, Pentasa].

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Danish Health and Medicines Authority.Mesalazine (Asacol, Pentasa) for the treatment of ulcerative colitis, Crohn's disease and renal impairment. Danish Pharmacovigilance Update 3: 6, No. 4, 19 Apr 2012. Available from: URL: http://laegemiddelstyrelsen.dk

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The Danish Health and Medicines Authority has issued guidance regarding the risk of renal impairment with mesalazine [Asacol, Pentasa].. React. Wkly. 1412, 4 (2012). https://doi.org/10.2165/00128415-201214120-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214120-00011

Keywords

Search

Navigation